Danaher Co. (DHR) Stake Raised by Schroder Investment Management Group

Schroder Investment Management Group lifted its stake in shares of Danaher Co. (NYSE:DHR) by 1.2% during the fourth quarter, HoldingsChannel.com reports. The firm owned 1,019,371 shares of the conglomerate’s stock after purchasing an additional 12,136 shares during the quarter. Schroder Investment Management Group’s holdings in Danaher were worth $94,618,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. raised its position in shares of Danaher by 1.3% during the second quarter. Vanguard Group Inc. now owns 41,488,407 shares of the conglomerate’s stock worth $3,501,206,000 after purchasing an additional 520,776 shares during the period. FMR LLC raised its position in shares of Danaher by 0.9% during the second quarter. FMR LLC now owns 19,624,350 shares of the conglomerate’s stock worth $1,656,100,000 after purchasing an additional 183,183 shares during the period. Parnassus Investments CA raised its position in shares of Danaher by 0.3% during the third quarter. Parnassus Investments CA now owns 9,796,584 shares of the conglomerate’s stock worth $840,351,000 after purchasing an additional 29,381 shares during the period. Flossbach Von Storch AG raised its position in shares of Danaher by 17.2% during the third quarter. Flossbach Von Storch AG now owns 6,776,921 shares of the conglomerate’s stock worth $581,324,000 after purchasing an additional 994,902 shares during the period. Finally, Dodge & Cox raised its position in shares of Danaher by 3.0% during the second quarter. Dodge & Cox now owns 5,250,773 shares of the conglomerate’s stock worth $443,113,000 after purchasing an additional 151,550 shares during the period. 75.88% of the stock is currently owned by institutional investors.

Several research analysts recently weighed in on the company. Barclays assumed coverage on Danaher in a research report on Thursday. They set an “overweight” rating and a $110.00 price target on the stock. Argus upped their price target on Danaher from $100.00 to $115.00 and gave the company a “buy” rating in a research report on Thursday, February 1st. Royal Bank of Canada reissued a “hold” rating and set a $98.00 price target on shares of Danaher in a research report on Wednesday, January 31st. Stifel Nicolaus upped their price target on Danaher from $110.00 to $115.00 and gave the company a “buy” rating in a research report on Wednesday, January 31st. Finally, Morgan Stanley upped their price target on Danaher from $103.00 to $110.00 and gave the company an “overweight” rating in a research report on Wednesday, January 31st. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $100.68.

In other Danaher news, CFO Daniel L. Comas sold 62,989 shares of the company’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $101.96, for a total value of $6,422,358.44. Following the transaction, the chief financial officer now directly owns 227,805 shares of the company’s stock, valued at approximately $23,226,997.80. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP William K. Daniel sold 131,066 shares of the company’s stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $102.05, for a total value of $13,375,285.30. Following the completion of the transaction, the executive vice president now directly owns 270,523 shares in the company, valued at $27,606,872.15. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 237,043 shares of company stock worth $24,194,886. Insiders own 12.20% of the company’s stock.

Danaher Co. (NYSE:DHR) opened at $97.54 on Friday. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.43 and a quick ratio of 1.05. Danaher Co. has a 52-week low of $78.97 and a 52-week high of $104.82. The firm has a market capitalization of $67,946.36, a PE ratio of 24.20, a price-to-earnings-growth ratio of 2.05 and a beta of 1.04.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, January 30th. The conglomerate reported $1.19 earnings per share for the quarter, topping the consensus estimate of $1.16 by $0.03. Danaher had a return on equity of 11.36% and a net margin of 13.60%. The company had revenue of $5.09 billion for the quarter, compared to analyst estimates of $4.97 billion. During the same period in the prior year, the firm posted $1.05 EPS. The business’s revenue was up 10.9% compared to the same quarter last year. sell-side analysts anticipate that Danaher Co. will post 4.37 earnings per share for the current year.

The company also recently announced a quarterly dividend, which was paid on Friday, January 26th. Shareholders of record on Friday, December 29th were given a $0.14 dividend. This represents a $0.56 annualized dividend and a yield of 0.57%. The ex-dividend date was Thursday, December 28th. Danaher’s payout ratio is currently 15.86%.

COPYRIGHT VIOLATION NOTICE: This report was originally published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://stocknewstimes.com/2018/02/18/danaher-co-dhr-stake-raised-by-schroder-investment-management-group.html.

Danaher Profile

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply